Based on 10 original studies, this systematic review reported that PBT can be cost-effective for HPV-associated tumors and for younger patients. A clinically substantial decrease in toxicities (xerostomia, oral mucositis, dysphagia, and percutaneous endoscopic gastrostomy tube implantation) is necessary for patients to be cost-effective candidates for PBT. Appropriate patient selection is required.